top of page

"Done": ADHD-Prescribing Legal Case: What It Means for Stimulants and Non-Controlled ADHD Medications

Writer: K Cafaro
K Cafaro
Nov 7
9 min read

When a national ADHD prescribing company becomes the center of a federal legal case, it raises a fair question: will careful clinicians still prescribe stimulant medication when it is appropriate?


The short answer is, yes. Stimulants remain evidence-based treatments for many people with ADHD. The longer answer is that prescribers have to be more careful than ever. That does not mean suspicious, dismissive, or unwilling to treat. It means responsible prescribing, clear documentation, and a treatment plan that fits the person in front of the clinician.


The Done case has become a flashpoint because it sits at the intersection of telehealth, controlled substances, diagnosis quality, pharmacy scrutiny, and access to care. For patients who have already been diagnosed and treated with ADHD, it can feel unsettling. No one wants to be treated like a problem because they need medication that helps them function.


A better takeaway is this: stimulant prescribing requires guardrails, and non-controlled medication options deserve more attention than they often get. I thought about applying with this company (they pai VERY well!), but when I read about their business model, it felt more like a money-making scam or a "legal" way to provide stimulants with very little oversight. My gut said that I should stay away if I valued my license."


Eye-level view of a weekly pill organizer beside a notebook with handwritten focus goals
Medication decisions work best when they are paired with a clear treatment plan.

What the Done case is really about


Done is (was?) a telehealth company known for ADHD evaluation and medication management. Federal prosecutors brought a legal case alleging improper prescribing practices involving stimulant medications. The case drew attention because stimulant medications, such as amphetamine and methylphenidate products, are controlled substances under federal law.


That matters, but it does not mean every telehealth ADHD visit is unsafe or every stimulant prescription is suspect. A legal allegation against one company is not a diagnosis of the entire field.


The case highlights several larger concerns:


  • Whether evaluations were thorough enough before medication was prescribed

  • Whether follow-up visits were frequent and meaningful

  • Whether controlled substances were prescribed in a way that met medical standards

  • Whether business practices influenced clinical decisions

  • Whether pharmacies, insurers, and regulators could trust the documentation behind prescriptions


Those are not small issues. Stimulant medications can be very helpful, but they also carry risks. They can raise heart rate or blood pressure, worsen anxiety in some people, affect sleep, reduce appetite, and carry misuse or diversion concerns. Prescribers cannot treat them like casual refills.


For people with ADHD, the risk is that cases like this can create fear and stigma. Some patients worry they will be cut off from medication even when they have a valid diagnosis and a history of benefit. That should not be the goal of careful prescribing.


Good care should protect access and safety at the same time.


Why prescribers have to be careful with stimulants


Stimulant medications are Schedule II controlled substances in the United States. That classification does not mean they are “bad” medications. It means the law recognizes both medical value and potential for misuse.


Because of that, prescribers have legal and clinical duties that go beyond simply asking whether the medication works.


A careful clinician will usually pay attention to:


  • The original diagnosis and how it was made (symptoms need to start before age 14)

  • Current symptoms and functional impairment

  • Past medication trials, benefits, and side effects

  • Heart history, blood pressure, sleep, appetite, and anxiety

  • Substance use history and current risk factors

  • Prescription Drug Monitoring Program records (your controlled substance prescriptions are logged and reported to the state by your pharmacy)

  • Pharmacy fill patterns and early refill requests

  • Whether the dose still makes sense over time


That can feel frustrating if medication has been stable for years. But from the prescriber’s side, each prescription carries responsibility. A clinician has to be able to explain why the medication is appropriate, why the dose is reasonable, and how safety is being monitored.


This is why “quick refill” models can create problems. A stimulant prescription without enough clinical context may not meet the standard of care. Pharmacies may also refuse prescriptions if they see red flags, even when the patient is acting in good faith. Multiple major pharmacy chains stopped filling the stimulant orders from Done due to concerns. In at least one case, refills were prescribed for a patient who was deceased, apparently before the refill had been requested.


People searching for “Stimulants medications prescribing” or "ADHD medication prescribers" are usually asking the same core question in a few different ways: why is this process so strict, and what does a legitimate prescriber need before writing the prescription?


The answer is not one single form or rule. It is the full picture.


Prescribing for people who were previously diagnosed


A prior ADHD diagnosis matters. It gives the prescriber a starting point. But it does not remove the need for review.


For patients who were previously diagnosed, a responsible clinic may still prescribe medication when the records and current clinical picture support it. That is different from starting from scratch, but it is not the same as automatic continuation.


A prescriber may ask for:


  • Previous diagnostic records, if available

  • Medication history from prior clinicians

  • Pharmacy records or refill history

  • Current symptom review

  • Current medical history and vital signs

  • Information about sleep, anxiety, mood, and substance use

  • Permission to coordinate with another clinician when needed

  • Some prescribers have spoken with patient parents (even when the patients are well into adulthood)


Not everyone has perfect records. Some people were diagnosed years ago. Some moved states. Some were diagnosed in childhood and no longer have paperwork. That does not automatically end the conversation.


It does mean the clinician may need to rebuild enough of the clinical record to prescribe safely. That might include rating scales, a detailed history, collateral information when appropriate, or a more complete evaluation.


The key is that prescribing should be based on documented medical need, not pressure, convenience, or a business model.


For patients, one of the most helpful steps is to gather what you can before the appointment:


  • Names and doses of past medications

  • What helped and what did not

  • Side effects you remember

  • Any reason a medication was stopped

  • Records from prior prescribers, if available

  • Blood pressure readings, especially if you monitor at home

  • A list of current medications and supplements


This makes the visit more useful. It also helps the prescriber make a decision that is defensible and patient-centered.


Close-up of a blood pressure cuff beside a medication bottle and a written symptom checklist
Safe prescribing includes both symptom tracking and basic health monitoring.

Non-controlled ADHD medications are real options


Stimulants often get the most attention because they can work quickly and have strong evidence behind them. But they are not the only option.


The medication world for ADHD has changed drastically in the last few years, and, in my opinion, for the better. Almost all ADHD medications have historically been highly controlled substances at a Schedule II (LSD, heroin etc. are a Schedule I and only for research purposes). Several ADHD medications are not controlled substances, especially newer medications. These can be useful for people who do not tolerate stimulants, prefer to avoid controlled medications, have certain risk factors, or need coverage outside the time frame when a stimulant is active.


ADHD medications:

Brand name

Generic name

Controlled?

DEA schedule

FDA-approved for ADHD?

Adderall

Mixed amphetamine salts

Yes

II

Yes

Adderall XR

Mixed amphetamine salts ER

Yes

II

Yes

Adzenys XR-ODT

Amphetamine ER

Yes

II

Yes

Aplenzin

Bupropion hydrobromide ER

No

N/A

No – Off-label

Aptensio XR

Methylphenidate ER

Yes

II

Yes

Azstarys

Serdexmethylphenidate/dexmethylphenidate

Yes

II

Yes

Daytrana

Methylphenidate transdermal

Yes

II

Yes

Desoxyn

Methamphetamine hydrochloride

Yes

II

Yes

Dexedrine

Dextroamphetamine

Yes

II

Yes

Dexedrine Spansule

Dextroamphetamine ER

Yes

II

Yes

Dyanavel XR

Amphetamine ER

Yes

II

Yes

Evekeo

Amphetamine sulfate

Yes

II

Yes

Evekeo ODT

Amphetamine sulfate

Yes

II

Yes

Focalin

Dexmethylphenidate

Yes

II

Yes

Focalin XR

Dexmethylphenidate ER

Yes

II

Yes

Intuniv

Guanfacine ER

No

N/A

Yes

Jornay PM

Methylphenidate DR/ER

Yes

II

Yes

Kapvay

Clonidine ER

No

N/A

Yes

Metadate CD

Methylphenidate ER

Yes

II

Yes

Metadate ER

Methylphenidate ER

Yes

II

Yes

Methylin

Methylphenidate

Yes

II

Yes

Mydayis

Mixed amphetamine salts ER

Yes

II

Yes

Norpramin

Desipramine

No

N/A

No – Off-label

Nuvigil

Armodafinil

Yes

IV

No – Off-label

Onyda XR

Clonidine ER

No

N/A

Yes

Pamelor

Nortriptyline

No

N/A

No – Off-label

ProCentra

Dextroamphetamine

Yes

II

Yes

Provigil

Modafinil

Yes

IV

No – Off-label

Qelbree

Viloxazine ER

No

N/A

Yes

Quillichew ER

Methylphenidate ER

Yes

II

Yes

Quillivant XR

Methylphenidate ER

Yes

II

Yes

Relexxii

Methylphenidate ER

Yes

II

Yes

Ritalin

Methylphenidate

Yes

II

Yes

Ritalin LA

Methylphenidate ER

Yes

II

Yes

Strattera

Atomoxetine

No

N/A

Yes

Tofranil

Imipramine

No

N/A

No – Off-label

Wellbutrin SR

Bupropion SR

No

N/A

No – Off-label

Wellbutrin XL

Bupropion XL

No

N/A

No – Off-label

Xelstrym

Dextroamphetamine transdermal

Yes

II

Yes

Zenzedi

Dextroamphetamine

Yes

II

Yes

Abbreviations: ER = extended-release; DR = delayed-release; ODT = orally disintegrating tablet; N/A = not applicable.


Understanding the DEA classifications

  • Schedule II: High potential for abuse and dependence; accepted medical use. Includes prescription amphetamine and methylphenidate stimulants.

  • Schedule IV: Lower potential for abuse and dependence relative to Schedule III substances. Includes modafinil and armodafinil.

  • Not controlled: No federal DEA controlled-substance schedule. These medications still require prescriptions.


Clinical and educational disclaimer: This table is intended for educational purposes and is not a prescribing guide. FDA indications, product availability, and controlled-substance classifications should be verified against current FDA labeling and DEA regulations.


"Non-controlled" does not mean side-effect free. These medications still need medical oversight. For example, atomoxetine can cause nausea, appetite changes, sleep changes, or mood effects in some people. Guanfacine and clonidine can lower blood pressure or cause sedation. All medications have the risk of some type of side effect, including your over-the-counter Tylenol (acetaminophen) or Motrin (ibuprofen).


The difference is legal classification. These medications do not carry the same federal controlled substance rules as stimulants. That can make refills and pharmacy processing less complicated.


They may be especially worth discussing when:


  • Stimulants cause anxiety, insomnia, appetite loss, or blood pressure issues

  • There is a personal or family concern about misuse

  • A patient needs all-day symptom coverage

  • There are frequent gaps due to stimulant shortages

  • The prescriber wants to start treatment while records are being gathered

  • A patient prefers a daily non-controlled medication plan


Some people do best on a stimulant. Some do best on a non stimulant. Some use a combination under careful medical supervision. The right plan depends on symptoms, medical history, past response, side effects, and personal goals.


What careful prescribing should feel like


Careful prescribing should not feel like being interrogated. It should feel like a clinician is taking the condition seriously.


A good medication visit usually includes more than “Is it working?” The prescriber should ask what life looks like with the medication and without it. Work, school, driving, relationships, time management, emotional control, sleep, and daily tasks all matter.


A careful plan may include:


  • A clear diagnosis or review of prior diagnosis

  • A reason for the medication choice

  • A starting dose or current dose rationale

  • A plan for follow-up

  • Monitoring for benefits and side effects

  • Clear refill expectations

  • Documentation of any concerns

  • Discussion of alternatives if the first plan is not a fit


Follow-up matters because ADHD treatment is not just about getting a prescription. The goal is better daily function with the least risk. That may mean adjusting dose, changing timing, switching medication, adding behavioral tools, or treating another condition that is making focus worse.


Anxiety, depression, trauma, sleep disorders, thyroid problems, substance use, and high stress can all affect attention. A clinician should be open to the full picture without using it to dismiss ADHD symptoms.


The best prescribing relationship has room for honesty. If a medication wears off too soon, say that. If it affects appetite, say that. If there are days when it feels too strong, say that. If a non stimulant sounds more comfortable, ask about it.


The Done case should not scare people away from treatment


The fear after a high-profile prescribing case is understandable. People who rely on medication may worry that prescribers will become too cautious to help. Pharmacies may seem more skeptical. Clinics may ask for more records. Follow-up rules may feel stricter.


Some of that may happen. But careful practice should not equal abandonment.


The right lesson is not, “Stop prescribing stimulants.” The right lesson is, “Prescribe only when the diagnosis, medical history, monitoring, and documentation support it.”


That protects patients too. It reduces unsafe prescribing, supports continuity of care, and helps legitimate prescriptions stand up to pharmacy and regulatory review.


It also creates a better opening to discuss non-controlled medications. For too long, many conversations have treated stimulants as the only serious option. They are an important option, but not the only one.


A thoughtful ADHD medication plan can include:


  • Continuing a stimulant when it is clearly appropriate

  • Switching stimulant class if side effects are a problem

  • Trying a non-controlled medication

  • Combining medication with skills-based support

  • Revisiting the diagnosis if the treatment response does not fit

  • Monitoring health markers over time


This kind of care takes more time than a quick refill model. It is also more likely to last.


A practical takeaway for patients with an existing diagnosis


If you have been previously diagnosed and are seeking medication management, the best preparation is simple: bring the story of your treatment in as much detail as you can.


You do not need to prove that you deserve help. But the prescriber does need enough information to make a safe and legal decision.


Before a visit, try to write down:


  • When you were diagnosed

  • Who diagnosed you, if you remember

  • What medications you have tried

  • Which dose worked best

  • What side effects you had

  • Why any medication was stopped

  • What symptoms are causing the most trouble now

  • Any medical changes since your last prescription


That makes the appointment more productive and helps the clinician choose between stimulant and non-controlled options.


Medication decisions should be careful, not cold. The Done case is a reminder that ADHD prescribing has legal and medical responsibilities, especially with stimulants. It is also a reminder that treatment can still be compassionate, practical, and individualized.


This article is for general information only and is not medical or legal advice. Medication decisions should be made with a licensed clinician who can review your history, risks, and treatment goals.


 
 
bottom of page